Juan Manuel O'Connor

Learn More
a Department of General Surgery, University of Verona, Verona , Italy; b Department of Surgery, Philipps University, Marburg , Germany; c Department of Endocrinology, University Hospital, Uppsala , Sweden; d Department of Pathology, Technical University of Munich, Munich , Germany; e Faculdade de Medicina do Porto & IPATIMUP, Porto , Portugal; f Instituto(More)
aDepartment of Gastroentereology and Clinical Medicine, St. James’s Hospital and Trinity College, Dublin, Ireland; bSt. Bartholomew, West Smithfield, London, UK; cDepartment of Endocrinology and Metabolism, Hadassah University Hospital, Jerusalem, Israel; dOspedale S. Andrea, Rome, Italy; eDepartment of Oncology, University Hospital, Prague, Czech Republic;(More)
a Digestive Diseases Branch, NIH, Bethesda, Md. , USA; b Division of General Surgery, Department of Surgery, Medical University of Vienna, Vienna , Austria; c Department of Hepatology and Gastroenterology, CHV A Pare Hospital, Boulogne , France; d Department of Gastroenterology, North Hampshire Hospital, Hampshire , UK; e Department of Surgery, Vivantes(More)
INTRODUCTION Somatostatin receptors are expressed in a large number of human tumours. The somatostatin receptors types 1-5 expression in a series including 100 gastro-entero-pancreatic endocrine tumours were analysed. METHODS From a prospectively built database of patients with gastro-entero-pancreatic endocrine tumours referred from three institutions,(More)
BACKGROUND The non-surgical management in a selected group of rectal cancer patients has shown promising results with adequate follow up. AIMS describing the results of the non-surgical management in patients with complete clinical response, with a close follow up. METHODS Between 2006 and 2015, patients with rectal cancer, stages I-III, without(More)
Elevated circulating levels of chromogranin A (CgA) are found in the neuroendocrine tumors (NETs), but diagnostic usefulness of this marker is still debatable. To assess the role of CgA for the identification and follow up of gastroenteropancreatic neuroendocrine tumors (GEP-NET), a multicenter prospective longitudinal study has been carried out in(More)